Table S6. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• The analysis indicates that FoundationOne Liquid CDx effectively detects BRAF V600E mutations.
• Sensitivity analysis shows promising efficacy rates for the F1LCDx+ population in colorectal cancer.
• Clinical validity of the test supports its integration into diagnostic processes for colorectal cancer.
• Results underscore the importance of targeted therapies for patients with BRAF V600E mutations.